7 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver diseaseRecruitingPhase 22026-10-09NCT07288138
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver diseaseRecruitingPhase 32026-10-08NCT07165028
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesBody Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutritionActive, not recruitingPhase 32026-10-06NCT07284901
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASHDigestive System Diseases, Fibrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver diseaseRecruitingPhase 32026-10-05NCT06419374
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)Digestive System Diseases, Fibrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver diseaseRecruitingPhase 32026-10-05NCT06318169
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutritionRecruitingPhase 32026-09-11NCT07654374
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related ComorbidityBody Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutritionActive, not recruitingPhase 22026-09-09NCT07497880